JP6247708B2 - 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 - Google Patents

虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 Download PDF

Info

Publication number
JP6247708B2
JP6247708B2 JP2015561314A JP2015561314A JP6247708B2 JP 6247708 B2 JP6247708 B2 JP 6247708B2 JP 2015561314 A JP2015561314 A JP 2015561314A JP 2015561314 A JP2015561314 A JP 2015561314A JP 6247708 B2 JP6247708 B2 JP 6247708B2
Authority
JP
Japan
Prior art keywords
cangrelor
pci
patients
administration
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015561314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510738A (ja
JP2016510738A5 (enExample
Inventor
クライブ アーサー アルキュラス−ミーンウェル，
クライブ アーサー アルキュラス−ミーンウェル，
シモーナ スカージャネック，
シモーナ スカージャネック，
ジェーン プラッツ，
ジェーン プラッツ，
デイビッド ジェイ． シュナイダー，
デイビッド ジェイ． シュナイダー，
Original Assignee
キエージィ ファーマチェウティチ エス．ペー．アー．
キエージィ ファーマチェウティチ エス．ペー．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed by キエージィ ファーマチェウティチ エス．ペー．アー．, キエージィ ファーマチェウティチ エス．ペー．アー． filed Critical キエージィ ファーマチェウティチ エス．ペー．アー．
Publication of JP2016510738A publication Critical patent/JP2016510738A/ja
Publication of JP2016510738A5 publication Critical patent/JP2016510738A5/ja
Application granted granted Critical
Publication of JP6247708B2 publication Critical patent/JP6247708B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015561314A 2013-03-09 2013-05-29 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法 Active JP6247708B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/792,056 2013-03-09
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US201361815735P 2013-04-25 2013-04-25
US61/815,735 2013-04-25
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017197488A Division JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法

Publications (3)

Publication Number Publication Date
JP2016510738A JP2016510738A (ja) 2016-04-11
JP2016510738A5 JP2016510738A5 (enExample) 2016-07-14
JP6247708B2 true JP6247708B2 (ja) 2017-12-13

Family

ID=51537409

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015561314A Active JP6247708B2 (ja) 2013-03-09 2013-05-29 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
JP2017197488A Withdrawn JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
JP2019137721A Active JP6840197B2 (ja) 2013-03-09 2019-07-26 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017197488A Withdrawn JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
JP2019137721A Active JP6840197B2 (ja) 2013-03-09 2019-07-26 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法

Country Status (10)

Country Link
EP (2) EP3978002A1 (enExample)
JP (3) JP6247708B2 (enExample)
CN (2) CN115120606A (enExample)
AU (1) AU2013381855B2 (enExample)
BR (1) BR112015022070B1 (enExample)
CA (1) CA2904523C (enExample)
EA (1) EA034550B1 (enExample)
ES (1) ES2904256T3 (enExample)
PL (1) PL2964233T3 (enExample)
WO (1) WO2014143107A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
WO2018234565A1 (en) * 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679721B2 (en) 1993-02-10 1997-07-10 Astrazeneca Ab N-alkyl-2-substituted ATP analogues
SE9604795D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
CA2747310C (en) * 2008-12-30 2018-02-06 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
SG176295A1 (en) * 2009-06-16 2012-01-30 Cardoz Ab Crystalline form of pemirolast
WO2011060066A2 (en) * 2009-11-11 2011-05-19 The Medicines Company Methods of treating or preventing stent thrombosis
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий

Also Published As

Publication number Publication date
EP2964233A1 (en) 2016-01-13
EP3978002A1 (en) 2022-04-06
EA034550B1 (ru) 2020-02-19
JP2018002739A (ja) 2018-01-11
JP2019178177A (ja) 2019-10-17
CN115120606A (zh) 2022-09-30
JP2016510738A (ja) 2016-04-11
AU2013381855A1 (en) 2015-10-22
EA201591683A1 (ru) 2016-08-31
BR112015022070A2 (pt) 2017-07-18
CN106102750A (zh) 2016-11-09
PL2964233T3 (pl) 2022-04-25
JP6840197B2 (ja) 2021-03-10
BR112015022070B1 (pt) 2022-01-18
EP2964233A4 (en) 2016-10-19
ES2904256T3 (es) 2022-04-04
CA2904523A1 (en) 2014-09-18
CA2904523C (en) 2024-01-09
WO2014143107A1 (en) 2014-09-18
AU2013381855B2 (en) 2018-08-02
EP2964233B1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
US11351187B2 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20220008540A1 (en) Methods of treating or preventing stent thrombosis
US11633419B2 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8680052B1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2014142780A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
MX2011005376A (es) Metodo para reducir trombocitopenia y mortalidad asociada a trombocitopenia.
JP2024502821A (ja) 処置方法
WO2015054542A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
TW200409638A (en) Use of MELOXICAM in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170623

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171117

R150 Certificate of patent or registration of utility model

Ref document number: 6247708

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250